Health Care-Related Economic Burden of the Polycystic Ovary Syndrome during the Reproductive Life Span
The DOI matches its Crossref record; 89 of the 90 references it cites were found in a registry or an index.
Abstract
CONTEXT: The polycystic ovary syndrome (PCOS) is the most common endocrine abnormality of reproductive-aged women today, affecting approximately 6.6% of unselected reproductive-aged women (approximately 4 million women in the United States) (1990 National Institutes of Health criteria), and potentially represents a significant financial burden to our health care. OBJECTIVE: The objective of the study was to define, using current definitions and prevalence or incidence data, the minimal economic burden that PCOS in reproductive-aged women represents for the United States. DESIGN: The study design was a literature review. SETTING: The study was conducted at a tertiary care center. PATIENTS OR OTHER PARTICIPANTS: There were no patients or other participants. INTERVENTION(S): We performed a systematic review of the published medical literature to identify studies evaluating epidemiology of reproductive-age PCOS and its clinical consequences and costs. We tied general societal cost data for the different health consequences to reproductive-age PCOS costs, using prevalence data. MAIN OUTCOME MEASURE(S): The main measure in the study was total health care-related economic costs. RESULTS: We estimated the mean annual cost of the initial evaluation to be dollar 93 million (2.1% of total costs), that of hormonally treating menstrual dysfunction/abnormal uterine bleeding to be dollar 1.35 billion (31.0% of total), that of providing infertility care to be dollar 533 million (12.2% of total), that of PCOS-associated diabetes to be dollar 1.77 billion (40.5% of total), and that of treating hirsutism to be dollar 622 million (14.2% of total). CONCLUSIONS: The total cost of evaluating and providing care to reproductive-aged PCOS women in the United States is dollar 4.36 billion. Because the cost of the diagnostic evaluation accounted for a relatively minor part of the total costs (approximately 2%), more widespread and liberal screening for the disorder appears be a cost-effective strategy, leading to earlier diagnosis and intervention and possibly the amelioration and prevention of serious sequelae.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“comprehensive screening and counseling from physicians and greater public awareness can curtail morbidity and reduce the economic burden on both the patient and the healthcare system.”
From 'I'm usually being my own doctor': women's experiences of managing polycystic ovary syndrome in Canada (2023) · cites this paper as [61]
In the citing paper
“PCOS has a high healthcare-related economic burden”
From 'I'm usually being my own doctor': women's experiences of managing polycystic ovary syndrome in Canada (2023) · cites this paper as [61]
In the citing paper
“Also from a resource allocation perspective, the financial costs related to diagnosis of PCOS are only a small fraction (2%) of the total costs associated with comprehensive care for PCOS in the United States (32).”
From Delayed Diagnosis and a Lack of Information Associated With Dissatisfaction in Women With Polycystic Ovary Syndrome (2016) · cites this paper as [32]
Citations
Cites
(2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.10.004 · Cited by 9,050
Economic Costs of Diabetes in the U.S. in 2002
American Diabetes Association (2003) · Diabetes Care · doi:10.2337/diacare.26.3.917 · Cited by 4,147
The Prevalence and Features of the Polycystic Ovary Syndrome in an Unselected Population
Azziz, R., Woods, K. S., Reyna, R., Key, T. J., Knochenhauer, E. S., & Yildiz, B. O. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032046 · Cited by 2,712
Self-citationMen at risk: occupation and male infertility
Claman, P. (2004) · Fertility and Sterility · doi:10.1016/s0015-0282(03)01188-9 · Cited by 2,387
Amenorrhea associated with bilateral polycystic ovaries
Stein, I. F., & Leventhal, M. L. (1935) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(15)30642-6 · Cited by 2,121
Legro, R. S. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.1.165 · Cited by 1,743
Knochenhauer, E. S., Key, T. J., Kahsar-Miller, M., Waggoner, W., Boots, L. R., & Azziz, R. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.9.5090 · Cited by 1,516
Self-citationAsunción, M., Calvo, R. M., San Millán, J. L., Sancho, J., Avila, S., & Escobar-Morreale, H. F. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.7.6682 · Cited by 1,318
Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.
Ehrmann, D. A., Barnes, R. B., Rosenfield, R. L., Cavaghan, M. K., & Imperial, J. (1999) · Diabetes Care · doi:10.2337/diacare.22.1.141 · Cited by 1,257
Androgen Excess in Women: Experience with Over 1000 Consecutive Patients
Azziz, R., Sanchez, L. A., Knochenhauer, E. S., Moran, C., Lazenby, J., Stephens, K. C., Taylor, K., & Boots, L. R. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031122 · Cited by 1,132
Self-citation
Cited by
Items 101–200 of 556
Kelley, A. S., Smith, Y. R., & Padmanabhan, V. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00383 · Cited by 79
Young women's experiences living with polycystic ovary syndrome
Weiss, T. R., & Bulmer, S. M. (2011) · Journal of Obstetric, Gynecologic & Neonatal Nursing · doi:10.1111/j.1552-6909.2011.01299.x · Cited by 73
Mousa, S., Brady, Mousa, S., & Mousa (2009) · Drug, Healthcare and Patient Safety · doi:10.2147/dhps.s4388 · Cited by 63
“It can be estimated that 50% of PCOS patients will actively seek infertility services at some point in their lifetime.(24) Further studies need to be performed to assess whether or not these patients who seek infertility services were better informed about fertility and had better quality of life, because they felt mo…”
Polycystic Ovarian Syndrome: Long-Term Health Consequences
Zore, T., Joshi, N., Lizneva, D., & Azziz, R. (2017) · Seminars in Reproductive Medicine · doi:10.1055/s-0037-1603096 · Cited by 72
Self-citationof the Drug and Therapeutics Committee of the Pediatric Endocrine Society, Geller, D. H., Pacaud, D., Gordon, C. M., & Misra, M. (2011) · International Journal of Pediatric Endocrinology · doi:10.1186/1687-9856-2011-9 · Cited by 72
“Hyperinsulinemia consequent to obesity and IR places women with PCOS at far greater risk to develop type 2 diabetes (T2DM) than healthy controls [15]: 15-36% of all T2DM reported in women, irrespective of age, is found in association with PCOS [14,16-19].”
BackgroundZhang, J., Zhu, Y., Wang, J., Hu, H., Jin, Y., Mao, X., Zhang, H., Yang, Y., Xin, X., & Li, D. (2024) · PLoS ONE · doi:10.1371/journal.pone.0306991 · Cited by 80
“By 2020, the economic burden of PCOS was assessed as 8 billion dollars per year [6, 7].”
BackgroundObesity and insulin resistance associated with lower plasma vitamin B12 in PCOS
Kaya, C., Cengiz, S. D., & Şatıroğlu, H. (2009) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2009.06.005 · Cited by 80
Brown, R. E., Wilkinson, D. A., Imran, S. A., Caraty, A., & Wilkinson, M. (2012) · Brain Research · doi:10.1016/j.brainres.2012.05.049 · Cited by 74
Cutaneous manifestations of polycystic ovary syndrome: A cross-sectional clinical study
Keen, M. A., Shah, I., & Sheikh, G. (2017) · Indian Dermatology Online Journal · doi:10.4103/2229-5178.202275 · Cited by 87
“8–34%.[20,21] One study among 129 women seen at a dermatology clinic for acne found that 19% met the criteria for PCOS defined by menstrual disturbances,”
BackgroundPundir, J., Charles, D., Sabatini, L., Hiam, D., Jitpiriyaroj, S., Teede, H., Coomarasamy, A., Moran, L., & Thangaratinam, S. (2019) · Human Reproduction Update · doi:10.1093/humupd/dmy045 · Cited by 63
Siristatidis, C., Sergentanis, T. N., Vogiatzi, P., Kanavidis, P., Chrelias, C., Papantoniou, N., & Psaltopoulou, T. (2015) · PLOS ONE · doi:10.1371/journal.pone.0134696 · Cited by 68
“Introduction Polycystic ovarian syndrome (PCOS) occurs in 5% to 10% of all women of reproductive age and 50% of women who present with sub-fertility [1].”
BackgroundPolycystic Ovary Syndrome: the Epigenetics Behind the Disease
Eiras, M. C., Pinheiro, D. P., Romcy, K. A. M., Ferriani, R. A., dos Reis, R. M., & Furtado, C. L. M. (2021) · Reproductive Sciences · doi:10.1007/s43032-021-00516-3 · Cited by 76
“The prevalence of PCOS may vary depending on the diagnosis criteria; it affects 5–20% of womenworldwide, thereby being the main cause of anovulatory infertility [10].”
BackgroundJoo, Y. Y., Actkins, K., Pacheco, J. A., Basile, A. O., Carroll, R., Crosslin, D. R., Day, F., Denny, J. C., Velez Edwards, D. R., Hakonarson, H., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz326 · Cited by 63
Reproductive endocrinology of adolescent polycystic ovary syndrome
Shayya, R., & Chang, R. (2010) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2009.02421.x · Cited by 65
Itchy-Dry Eye Associated with Polycystic Ovary Syndrome
Bonini, S., Mantelli, F., Moretti, C., Lambìase, A., Bonini, S., & Micera, A. (2007) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.01.030 · Cited by 71
Polycystic ovarian syndrome – prognosis and outcomes
Hart, R. J., & Norman, R. J. (2006) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2006.04.006 · Cited by 68
Fraser, G. L., Obermayer-Pietsch, B. M., Laven, J. S. E., Griesinger, G., Pintiaux, A., Timmerman, D., Fauser, B. C. J. M., Lademacher, C., Combalbert, J., Hoveyda, H. R., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab320 · Cited by 69
“5 INTRODUCTION Polycystic ovary syndrome (PCOS) is the leading cause of anovulatory infertility and the most common endocrine disorder in reproductive-aged women (1), with an estimated global prevalence of approximately 10% (2) and related annual medical costs exceeding $4 billion in the United States (3, 4).”
BackgroundDing, T., Baio, G., Hardiman, P. J., Petersen, I., & Sammon, C. (2016) · BMJ Open · doi:10.1136/bmjopen-2016-012461 · Cited by 56
“Further work is therefore needed to inform women and healthcare professionals about the condition to avoid any worsening of the disease or rapid conversion into other metabolic disorders considering the relatively low cost of diagnosis and high cost of care for the associated diseases suggested by Azziz et al.(30) The…”
BackgroundChiavaroli, V., Liberati, M., D’Antonio, F., Masuccio, F. G., Capanna, R., Verrotti, A., Chiarelli, F., & Mohn, A. (2010) · European Journal of Endocrinology · doi:10.1530/eje-09-1102 · Cited by 65
Porter, D. T., Moore, A. M., Cobern, J. A., Padmanabhan, V., Goodman, R. L., Coolen, L. M., & Lehman, M. N. (2019) · Endocrinology · doi:10.1210/en.2019-00137 · Cited by 65
Complex diseases and co-morbidities: polycystic ovary syndrome and type 2 diabetes mellitus
Rodgers, R. J., Avery, J. C., Moore, V. M., Davies, M. J., Azziz, R., Stener-Victorin, E., Moran, L. J., Robertson, S. A., Stepto, N. K., Norman, R. J., et al. (2019) · Endocrine Connections · doi:10.1530/ec-18-0502 · Cited by 60
Self-citationHyperandrogenaemia in adolescent girls: origins of abnormal gonadotropin‐releasing hormone secretion
Burt Solorzano, C., McCartney, C., Blank, S., Knudsen, K., & Marshall, J. (2010) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2009.02383.x · Cited by 56
Hallajzadeh, J., Khoramdad, M., Karamzad, N., Almasi‐Hashiani, A., Janati, A., Ayubi, E., Pakzad, R., Sullman, M. J. M., & Safiri, S. (2018) · Journal of Cardiovascular and Thoracic Research · doi:10.15171/jcvtr.2018.10 · Cited by 76
“J Cardiovasc Thorac Res, 2018, 10(2), 56-69”
BackgroundMethodInfluentialLin, T.-Y., Lin, P.-Y., Su, T., Li, C., Lin, W.-C., Chang, W.-H., Chen, T., Bai, Y., & Chen, M. (2017) · Sleep Medicine · doi:10.1016/j.sleep.2016.12.029 · Cited by 66
Ouyang, P., Wenger, N. K., Taylor, D., Rich-Edwards, J. W., Steiner, M., Shaw, L. J., Berga, S. L., Miller, V. M., & Merz, N. B. (2016) · Biology of Sex Differences · doi:10.1186/s13293-016-0073-y · Cited by 51
“Polycystic ovary syndrome (PCOS) is a common condition that affects approximately 5 % of women of reproductive age in the USA [79, 80] and is estimated to cost $4 billion annually in health-care costs [81].”
BackgroundBehboodi Moghadam, Z., Fereidooni, B., Saffari, M., & Montazeri, A. (2018) · BMC Women's Health · doi:10.1186/s12905-018-0658-1 · Cited by 50
Baicalin ameliorates polycystic ovary syndrome through AMP-activated protein kinase
Wang, W., Zheng, J., Cui, N., Jiang, L., Zhou, H., Zhang, D., & Hao, G. (2019) · Journal of Ovarian Research · doi:10.1186/s13048-019-0585-2 · Cited by 57
“36 billion to treat PCOSrelated reproductive dysfunction and metabolic disorders [3].”
BackgroundThe neuroendocrine genesis of polycystic ovary syndrome: A role for arcuate nucleus GABA neurons
Moore, A. M., & Campbell, R. E. (2015) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2015.10.002 · Cited by 56
Li, R., Yu, G., Yang, D., Li, S., Lu, S., Wu, X., Wei, Z., Song, X., Wang, X., Fu, S., et al. (2014) · BMC Endocrine Disorders · doi:10.1186/1472-6823-14-76 · Cited by 57
“The predisposition of PCOS women to various metabolic disturbances, including obesity, IGT, atherogenic dyslipidaemia and hypertension, increased in the long-term risk of DM2 and cardiovascular disease (CVD), which indicated that PCOS carried significant public health implication [10].”
BackgroundHosseinzadeh, F. M., Hosseinzadeh‐Attar, M. J., Yekaninejad, M. S., & Rashidi, B. H. (2016) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2016.01.002 · Cited by 57
Zhang, C., Liu, J., Lai, M., Li, J., Zhan, J., Wen, Q., & Ma, H. (2019) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-019-05129-5 · Cited by 58
Arya, B. K., Haq, A. U., & Chaudhury, K. (2012) · Medical Hypotheses · doi:10.1016/j.mehy.2012.01.009 · Cited by 53
“An estimated average annual cost of infertility care for PCOS is $533 million assuming that demand for infertility care is distributed uniformly over the entire reproductive lifespan of 30 years [1,2].”
BackgroundShorakae, S., Boyle, J., & Teede, H. (2014) · Internal Medicine Journal · doi:10.1111/imj.12495 · Cited by 49
Orio, F., Giallauria, F., Palomba, S., Manguso, F., Orio, M., Tafuri, D., Lombardi, G., Carmina, E., Colao, A., & Vigorito, C. (2008) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2007.03117.x · Cited by 50
Androgens in Polycystic Ovary Syndrome: The Role of Exercise and Diet
Giallauria, F., Palomba, S., Vigorito, C., Tafuri, M. G., Colao, A., Lombardi, G., & Orio, F. (2009) · Seminars in Reproductive Medicine · doi:10.1055/s-0029-1225258 · Cited by 50
“Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in premenopausal women, with 6 to 7% prevalence worldwide.(1,2) This syndrome is a heterogeneous disorder characterized by chronic ovulatory dysfunction and hyperandrogenism.”
BackgroundKarimi, E., Heshmati, J., Shirzad, N., Vesali, S., Hosseinzadeh‐Attar, M. J., Moini, A., & Sepidarkish, M. (2020) · Lipids in Health and Disease · doi:10.1186/s12944-020-01244-4 · Cited by 54
“There is a great deal of cost on health systems resulting from complications associated with PCOS [8].”
Ezeh, U., Ezeh, C., Pisarska, M. D., & Azziz, R. (2021) · Fertility and Sterility · doi:10.1016/j.fertnstert.2020.12.015 · Cited by 50
Self-citationGiallauria, F., Palomba, S., Manguso, F., Vitelli, A., Maresca, L., Tafuri, D., Lombardi, G., Colao, A., Vigorito, C., & Orio, F. (2008) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2007.03004.x · Cited by 51
Karimi, E., Moini, A., Yaseri, M., Shirzad, N., Sepidarkish, M., Hossein-Boroujerdi, M., & Hosseinzadeh-Attar, M. J. (2018) · British Journal of Nutrition · doi:10.1017/s0007114517003920 · Cited by 50
“It also has serious economic consequences((3)).”
BackgroundMousa, M., Al‐Jefout, M., AlSafar, H. S., Kirtley, S., Lindgren, C. M., Missmer, S. A., Becker, C. M., Zondervan, K. T., & Rahmioğlu, N. (2021) · Frontiers in Reproductive Health · doi:10.3389/frph.2021.661360 · Cited by 59
“(5); (6); (7); (2) ; (8); (9) ; (10); (11); (12) ; (4) ; (13) ; (14) ; (15); (16); (17); (18); (19); (20) ; (21); (22); (23); (24) ; (25); (3) ; (26) ; (27) .”
Polycystic Ovary Syndrome: Insights into the Therapeutic Approach with Inositols
Sortino, M. A., Salomone, S., Carruba, M. O., & Drago, F. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00341 · Cited by 49
“This issue is of particular interest, considering the economic and social burden of PCOS (Azziz et al., 2005), which not only represents a leading cause of female infertility worldwide (Conway et al., 2014; Joham et al., 2015), but has also been associated with a higher risk of ovarian cancer…”
BackgroundComparison of Dietary Intake between Polycystic Ovary Syndrome Women and Controls
Shishehgar, F., Ramezani Tehrani, F., Mirmiran, P., Hajian, S., Baghestani, A. R., & Moslehi, N. (2016) · Global Journal of Health Science · doi:10.5539/gjhs.v8n9p302 · Cited by 49
Modified Ferriman–Gallwey hirsutism score and androgen levels in Turkish women
Coşkun, A., Ercan, Ö., Arıkan, D. C., Özer, A., Kılınç, M., Kıran, G., & Köstü, B. (2010) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2010.10.001 · Cited by 52
Atiomo, W., Khalid, S., Parameshweran, S., Houda, M. R., & Layfield, R. (2008) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2008.02041.x · Cited by 50
Polycystic Ovary Syndrome as a systemic disease with multiple molecular pathways: a narrative review
Carvalho, L. M. L., dos Reis, F. M., Cândido, A. L., Nunes, F. F. C., Ferreira, C. N., & Gomes, K. B. (2018) · Endocrine Regulations · doi:10.2478/enr-2018-0026 · Cited by 55
“Although it is significantly expensive for the health system, the understanding of its pathophysiology is very relevant (Azziz et al. 2005).”
BackgroundGlueck, C. J., Aregawi, D., Winiarska, M., Agioria, M., Luo, G., Sieve, L., & Wang, P. (2006) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem.2006.19.6.831 · Cited by 48
Mahoney, D. (2014) · Journal of the American Association of Nurse Practitioners · doi:10.1002/2327-6924.12073 · Cited by 42
Ruan, X., Kubba, A., Aguilar, A., & Mueck, A. O. (2017) · The European Journal of Contraception & Reproductive Health Care · doi:10.1080/13625187.2017.1317735 · Cited by 47
Ghandi, S., Aflatoonian, A., Tabibnejad, N., & Moghaddam, M. H. S. (2011) · Journal of Assisted Reproduction and Genetics · doi:10.1007/s10815-011-9564-2 · Cited by 47
“Hyperinsulinemia and insulin resistance may contribute to increased risk of developing type II diabetes, hypertension and the adverse cardiovascular risk [11].”
BackgroundRani, R., Hajam, Y. A., Kumar, R., Bhat, R. A., Rai, S., & Rather, M. A. (2021) · Phytomedicine Plus · doi:10.1016/j.phyplu.2021.100161 · Cited by 50
Siristatidis, C. S., Maheshwari, A., Vaidakis, D., & Bhattacharya, S. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006606.pub4 · Cited by 48
“[DOI: https://doi.org/10.1016/ j.bpobgyn.2004.05.007] Azziz 2005 Azziz R, Marin C, Hoq L, Badamgarav E, Song P. Health carerelated economic burden of the polycystic ovary syndrome during the reproductive life span.”
InfluentialChoi, Y. S., Yang, H. I., Cho, S., Jung, J. A., Jeon, Y. E., Kim, H. Y., Seo, S. K., & Lee, B. S. (2012) · Steroids · doi:10.1016/j.steroids.2012.08.005 · Cited by 51
Amato, M. C., Galluzzo, A., Finocchiaro, S., Criscimanna, A., & Giordano, C. S. D. S. (2008) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2007.03145.x · Cited by 51
Knowledge of PCOS in physicians-in-training: identifying gaps and educational opportunities
Chemerinski, A., Cooney, L., Shah, D., Butts, S., Gibson-Helm, M., & Dokras, A. (2020) · Gynecological Endocrinology · doi:10.1080/09513590.2020.1746761 · Cited by 45
Armanini, D., Bordin, L., Donà, G., Sabbadin, C., Bakdounes, L., Ragazzi, E., Giorgino, F. L., & Fiore, C. (2012) · Steroids · doi:10.1016/j.steroids.2012.02.010 · Cited by 45
“These patients frequently are obese and have an increased LH/FSH ratio [1,2].”
BackgroundLower serum apelin levels in women with polycystic ovary syndrome
Chang, C., Tsai, Y.-C., Lee, C., Chan, T., Wang, S., & Su, J.-H. (2011) · Fertility and Sterility · doi:10.1016/j.fertnstert.2011.04.044 · Cited by 47
Tfayli, H., Ulnach, J. W., Lee, S., Sutton-Tyrrell, K., & Arslanian, S. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2547 · Cited by 44
Serum fibroblast growth factor 21 levels in polycystic ovary syndrome
Görar, S., Çulha, C., Üç, Z. A., Dellal, F. D., Serter, R., Aral, S., & Aral, Y. (2010) · Gynecological Endocrinology · doi:10.3109/09513590.2010.487587 · Cited by 46
“In addition to diagnosing a women as having PCOS implies an increased risk for insulin resistance, glucose intolerance, type 2 diabetes mellitus, dyslipidaemia, hypertension and possibly cardiovascular disease [2,3].”
BackgroundA life course perspective on polycystic ovary syndrome
Sanchez, N. (2014) · International Journal of Women's Health · doi:10.2147/ijwh.s55748 · Cited by 43
Genetics of Polycystic Ovary Syndrome
Welt, C. K. (2021) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2020.10.006 · Cited by 43
Pharmacotherapy of polycystic ovary syndrome – an update
Saha, L., Kaur, S., & Saha, P. K. (2011) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2010.00916.x · Cited by 46
Glueck, C. J., Morrison, J. A., Goldenberg, N., & Wang, P. (2009) · Metabolism · doi:10.1016/j.metabol.2009.02.005 · Cited by 49
Sitagliptin Decreases Visceral Fat and Blood Glucose in Women With Polycystic Ovarian Syndrome
Devin, J. K., Nian, H., Celedonio, J. E., Wright, P., & Brown, N. J. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz028 · Cited by 42
Abbott, D. H., Rogers, J., Dumesic, D. A., & Levine, J. E. (2019) · Medical Sciences · doi:10.3390/medsci7120107 · Cited by 46
“PCOS thus places heavy burdens on health-care resources [8] that may exceed $14 billion annual costs in the US alone.”
BackgroundGao, T., Wu, L., Chang, F., & Cao, G. (2016) · Endocrine Journal · doi:10.1507/endocrj.ej15-0318 · Cited by 41
“In the United States, approximately 4 million women were affected with PCOS [2], with symptoms starting from adolescence to postmenopause [3].”
Diabetes risk score in the diagnostic categories of polycystic ovary syndrome
Moran, L. J., Strauss, B. J., & Teede, H. J. (2011) · Fertility and Sterility · doi:10.1016/j.fertnstert.2011.01.133 · Cited by 41
“The International Diabetes Federation identifies PCOS as an independent risk factor for DM2 (12) and 40% of PCOS-associated health costs are DM2 related (13).”
BackgroundA machine learning approach for non-invasive PCOS diagnosis from ultrasound and clinical features
Agirsoy, M., & Oehlschlaeger, M. A. (2025) · Scientific Reports · doi:10.1038/s41598-025-10453-9 · Cited by 51
“Since quality of life is closely tied to the clinical features of PCOS, early intervention improves health outcomes while also reducing the financial burden on both patients and healthcare systems 8,9 .”
Kujanpää, L., Arffman, R. K., Pesonen, P., Korhonen, E., Karjula, S., Järvelin, M., Franks, S., Tapanainen, J. S., Morin‐Papunen, L., & Piltonen, T. T. (2022) · Acta Obstetricia et Gynecologica Scandinavica · doi:10.1111/aogs.14382 · Cited by 40
Blackshaw, L. C. D., Chhour, I., Stepto, N. K., & Lim, S. S. (2019) · Medical Sciences · doi:10.3390/medsci7070076 · Cited by 40
“Majority of this cost stems from expensive fertility treatments and the long term chronic sequalae of IR and metabolic syndrome including DM2 and CVD [12].”
BackgroundGanie, M. A., & Kalra, S. (2011) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.85571 · Cited by 49
“In 2006, based on US data and traditionally lower prevalence estimates, the anticipated economic burden of PCOS in Australia was AU$400 million (menstrual dysfunction 31%, infertility 12% and PCOS-associated diabetes 40% of total costs), representing a major health and economic burden.[4] With regards to fertility, th…”
BackgroundThe Improvement and Clinical Application of Human Oocyte In Vitro Maturation (IVM)
Gong, X., Li, H., & Zhao, Y. (2021) · Reproductive Sciences · doi:10.1007/s43032-021-00613-3 · Cited by 39
Ismayilova, M., & Yaya, S. (2023) · International Health · doi:10.1093/inthealth/ihac028 · Cited by 38
Ding, T., Hardiman, P. J., Petersen, I., & Baio, G. (2018) · Human Reproduction · doi:10.1093/humrep/dey093 · Cited by 38
“36 71 billion per year, with treatment of type 2 diabetes accounting for over 40% of the costs 72 (Azziz et al., 2005).”
BackgroundAuble, B., Elder, D., Gross, A., & Hillman, J. B. (2013) · Journal of Pediatric and Adolescent Gynecology · doi:10.1016/j.jpag.2013.03.007 · Cited by 35
“Our goals were to establish within and then compare across the 3 pediatric specialties: (1) the percentage of individuals identified with an ICD-9 diagnosis of PCOS who met diagnostic criteria; (2) the percentage of individuals who were screened for comorbidities; (3) the treatment recommendations; (4) factors associa…”
BackgroundStatus of clomiphene citrate and metformin for infertility in PCOS
Misso, M. L., Teede, H. J., Hart, R. J., Wong, J., Rombauts, L. J. F., Melder, A., Norman, R. J., & Costello, M. (2012) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2012.07.001 · Cited by 39
Silva, R. D. C., Pardini, D., & Kater, C. E. (2006) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302006000200014 · Cited by 76
Proteomics and polycystic ovary syndrome
Insenser, M. R., & Escobar-Morreale, H. F. (2013) · Expert Review of Proteomics · doi:10.1586/14789450.2013.837665 · Cited by 37
Polycystic ovary syndrome among Indian adolescent girls – A systematic review and metanalysis
Sharma, M., Khapre, M. P., Saxena, V., & Kaushal, P. (2021) · Nepal Journal of Epidemiology · doi:10.3126/nje.v11i3.38460 · Cited by 44
Quercetin and polycystic ovary syndrome
Ma, C., Xiang, Q., Song, G., & Wang, X. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1006678 · Cited by 43
“About 50%–70% of PCOS patients have IR (Azziz et al., 2005), and up to 88% of women with PCOS are at risk of being overweight and obese (Barber et al., 2006; Lim et al., 2012).”
BackgroundKilic, S., Yilmaz, N., Zulfikaroglu, E., Erdogan, G., Aydin, M., & Batioglu, S. (2011) · Gynecological Endocrinology · doi:10.3109/09513590.2010.530706 · Cited by 35
“Polycystic ovary syndrome (PCOS) is the most frequent endocrine disorder of women in the reproductive age [1].”
BackgroundClinical, endocrine and ultrasonographic features of polycystic ovary syndrome in Thai women
Vutyavanich, T., Khaniyao, V., Wongtra‐ngan, S., Sreshthaputra, O., Sreshthaputra, R., & Piromlertamorn, W. (2007) · Journal of Obstetrics and Gynaecology Research · doi:10.1111/j.1447-0756.2007.00631.x · Cited by 36
Bode, D. V., Seehusen, D. A., & Baird, D. C. (2012) · PubMed · Cited by 75
Vrbikova, J., Dvorakova, K., Grimmichova, T., Hill, M., Stanicka, S., Cibula, D., Bendlova, B., Starka, L., & Vondra, K. (2007) · Clinical Chemical Laboratory Medicine · doi:10.1515/cclm.2007.113 · Cited by 35
Metabolic and hormonal aspects of polycystic ovary syndrome: the impact of diet
O'Connor, A., Gibney, J., & Roche, H. M. (2010) · Proceedings of the Nutrition Society · doi:10.1017/s0029665110002016 · Cited by 21
“The efficacy of long-term lifestyle interventions has been highlighted by work conducted as part of a large-scale clinical trial aimed at preventing the onset of T2DM in high-risk individuals.”
InfluentialGhavi, F., Taghizadeh, M., Taebi, M., & Abdolahian, S. (2019) · Journal of Herbal Medicine · doi:10.1016/j.hermed.2019.100277 · Cited by 35
Polycystic ovarian syndrome – prognosis and treatment outcomes
Hart, R. (2007) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0b013e3282f10e22 · Cited by 34
Kondo, M., Osuka, S., Iwase, A., Nakahara, T., Saito, A., Bayasula, Nakamura, T., Goto, M., Kotani, T., & Kikkawa, F. (2016) · Metabolic Brain Disease · doi:10.1007/s11011-016-9807-0 · Cited by 35
Naderpoor, N., Shorakae, S., Abell, S. K., Mousa, A., Joham, A. E., Moran, L., Stepto, N. K., Spritzer, P. M., Teede, H. J., & de Courten, B. V. (2017) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2017.07.012 · Cited by 34
Li, L., Zhang, J., Zeng, J., Liao, B., Peng, X., Li, T., Li, J., Tan, Q., Li, X., Yang, Y., et al. (2020) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2020.4522 · Cited by 39
“36 billion on medical care for its 4 million patients with PcOS in 2005 (5).”
Polycystic ovary syndrome (PCOS) trilogy: a translational and clinical review
Mason, H. D., Colao, A., Blume‐Peytavi, U., Rice, S., Qureshi, A., Pellatt, L. J., Orio, F., & Atkin, S. L. (2008) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03329.x · Cited by 37
Optimal management of subfertility in polycystic ovary syndrome
Bates, G. W., & Berger, J. (2014) · International Journal of Women s Health · doi:10.2147/ijwh.s48527 · Cited by 38
The Association Between Polycystic Ovary Syndrome and Its Dermatological Manifestations
Sekhon, A. K., Zergham, A. S., Tserenpil, G., Mebasher, A., & Malik, B. H. (2020) · Cureus · doi:10.7759/cureus.6855 · Cited by 36
“The Australian health system invests more than 800 million dollars annually in the treatment of this disease [13].”
BackgroundApproach to the Patient: Diagnostic Challenges in the Workup for Polycystic Ovary Syndrome
Joham, A. E., Tay, C. T., Laven, J. S. E., Louwers, Y. V., & Azziz, R. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae910 · Cited by 36
Self-citationGrigorescu, V. I., Zhang, Y., Kissin, D. M., Sauber‐Schatz, E. K., Sunderam, M., Kirby, R. S., Diop, H., McKane, P., & Jamieson, D. J. (2014) · Fertility and Sterility · doi:10.1016/j.fertnstert.2013.12.030 · Cited by 32
“Therefore, more widespread and liberal screening for the disorder appears be a cost-effective strategy, leading to earlier diagnosis and interventions followed by possible amelioration and prevention of serious sequelae (36).”
BackgroundZhang, F., Ma, T., Tong, X., Liu, Y., Cui, P., Xu, X., Shi, J., Hu, W., Lu, W., Pei, Z., et al. (2021) · Acupuncture in Medicine · doi:10.1177/09645284211056663 · Cited by 37
“Raw fastq files were demultiplexed, quality-filtered by Trimmomatic, and merged by FLASH with the following criteria: (1) reads were truncated at any site receiving an average quality score < 20 over a 50 bp sliding window; (2) primers were exactly matched allowing for 2-nucleotide mismatching and removal of reads con…”
MethodPolycystic ovary syndrome and acne.
Chuan, S. S., & Rj, C. (2010) · Skin therapy letter · Cited by 44
The obesogen tributyltin induces features of polycystic ovary syndrome (PCOS): a review
Merlo, E., Silva, I. V., Cardoso, R. C., & Graceli, J. B. (2018) · Journal of Toxicology and Environmental Health Part B · doi:10.1080/10937404.2018.1496214 · Cited by 33
“Increased risks for metabolic syndrome, T2DM and impaired glucose tolerance, and cardiovascular disease were observed in women with PCOS (Moran, Norman, and Teede 2015; Teede, Deeks, and Moran 2010).”
BackgroundInfluentialHatanaka, Y., Kabuta, T., & Wada, K. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00035 · Cited by 33
“Polycystic ovary syndrome (PCOS), characterized by ovarian dysfunction, and polycystic ovarian morphology in women of childbearing age, leads to excessive levels of male hormones, a condition called hyperandrogenism (Franks, 1995; Abbott et al., 2005; Azziz et al., 2005; Goodarzi et al., 2011), and children from PCOS…”
BackgroundContribution of real-time elastography in diagnosis of polycystic ovary syndrome
Çıracı, S., Tan, S., Özcan, A. N. Ş., Aslan, A., Keskin, H. L., Ateş, Ö. F., Akcay, Y., & Arslan, H. (2015) · Diagnostic and Interventional Radiology · doi:10.5152/dir.2014.14094 · Cited by 32
Martin, O., Lester, J. N., Voulvoulis, N., & Boobis, A. R. (2007) · Toxicological Sciences · doi:10.1093/toxsci/kfm008 · Cited by 37
“PCOS can be a cause of hirsutism, diabetes, and infertility (Azziz et al., 2005) and has also been associated with endometrial cancer in premenopausal women (Pillay et al.”
Background
Metadata
- Authors
- Azziz, R., Marin, C., Hoq, L., Badamgarav, E., & Song, P.
- Affiliations
- Cedars-Sinai Medical Center (US)
- ORCID
- Azziz, Ricardo
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2005-08
- Volume
- 90
- Issue
- 8
- Pages
- 4650-4658
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2118575626
- Cited by
- 537
- References
- 90
- Citations by year
- 2026: 20 · 2025: 30 · 2024: 29 · 2023: 28 · 2022: 36 · 2021: 45 · 2020: 25 · 2019: 41 · 2018: 27 · 2017: 27 · 2016: 22 · 2015: 20 · 2014: 27 · 2013: 24 · 2012: 26
- FWCI
- 18.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Public Health Service (K24-D01346)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01HD029364, R01-HD29364)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Reproductive Medicine › Reproductive Health and Technologies
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Keywords
- polycystic ovary syndrome, economic burden, health care costs, women of reproductive age, infertility treatment, hirsutism, abnormal uterine bleeding, menstrual disorders, PCOS screening, cost estimation
- MeSH terms
- Adolescent, Adult, Female, Humans, Polycystic Ovary Syndrome, United States, Incidence, Prevalence, Health Care Costs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.